(NASDAQ: WHWK) Whitehawk Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.47%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.28%.
Whitehawk Therapeutics's earnings in 2026 is -$79,831,000.On average, 10 Wall Street analysts forecast WHWK's earnings for 2026 to be -$71,272,664, with the lowest WHWK earnings forecast at -$97,770,452, and the highest WHWK earnings forecast at -$59,260,866. On average, 9 Wall Street analysts forecast WHWK's earnings for 2027 to be -$68,912,491, with the lowest WHWK earnings forecast at -$100,563,894, and the highest WHWK earnings forecast at -$49,683,352.
In 2028, WHWK is forecast to generate -$67,173,716 in earnings, with the lowest earnings forecast at -$97,770,452 and the highest earnings forecast at -$32,324,109.